The stocks on Wall Street posed a major downfall as more than 30 million US residents filed for unemployment benefits over the past few weeks due to the pandemic. The Dow Jones dropped 288.14 points to close at 24,345.72 levels. Also, other major Indices followed the same. On the other hand, global stocks followed the bearish trend, where European Indices such as CAC40 and FTSE100 closed in the red.

We see a change in the market trend after a boom in tech stocks last month. This month the stocks pick will be different as the tech stocks already are in overbought zone considering the market overall. Not every discounted stock is a good buy. Some of the stock hits a higher level, but some still remain attractive to buy for the long-term investment. Below is the list of 3 best stocks to invest in May 2020 for long-term goals.

1. Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) on 29 April 2020 has announced the topline results of the Phase 3 Trial of investigational antiviral Remdesivir in patients with severe COVID-19. The company found that the patients who received a 10-day treatment course of the medicine achieved similar improvement in clinical status compared with a 5-day treatment course.

Gilead Sciences Inc. is a well known American drug maker company that has developed the first major cure for hepatitis-C. In 2013, the company showed more than $10 billion in sales after a drug named Sovaldi that gained approval in 2013 by the respective department.

Coming to the fundamentals of the company, the EPS has declined to 14 from the past 16 quarters. In Q1, Gilead Science showed a 1% earning gain to $1.68 per share.

The sales rise 5% to $5.55 billion and beat the expectation by 10%. Last year, Gilead Science earnings were $6.63 per share, which were down a fraction on Y-o-Y basis. The Operating cash flow of the company is $6.69 per share, less than 1% ahead of profit.

2. GlaxoSmithKline

GlaxoSmithKline have also jumped to the race to combat coronavirus and started to work on development of vaccine. The shares of the company surged 14.8% over the past 30 days.

Separately, GSK and Vir Biotechnology Inc. announced last month, in which GSK made a $250 million equity investment in Vir as the two companies work together to develop two of Vir’s experimental therapies. It is expected to go to Phase 2 clinical trials sometime in 2020.

3. Heat Biologics

Heat Biologics Inc. has previously announced that it is working on a vaccine for the COVID-19 with the University of Miami Miller School of Medicine.

Heat Biologics Inc. [NASDAQ: HTBX] surged more than 3% on the last trading session, reaching $0.59 price per share at press time. The company represents 79.17 million in outstanding shares, while it has a total market value of $47.07 million with the latest information. In the last 12 months, the stock price of the company jumped by 25.18% due to the supporting fundamentals of the company.